Macquarie Group’s Alto Neuroscience ANRO Stock Holding History

Macquarie Group’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-473	Closed	-$7	–	2166
2024 Q1	$7	Buy	+473	New	+$7.4K	﹤0.01%	1757

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Macquarie Group's ANRO Position: Q2 2024 in Review

Macquarie Group sold out of Alto Neuroscience (ANRO) in Q2 2024, closing a stake of 473 shares — an estimated $7 sold.

Macquarie Group first reported a position in ANRO in Q1 2024 and held it in 1 quarter. The position peaked at $7 in Q1 2024. 58 funds tracked by Wall St. Rank hold ANRO as of Q2 2024.

Macquarie Group reported no remaining Alto Neuroscience position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 473 Alto Neuroscience shares in Q2 2024, an estimated $7.
Macquarie Group first reported a position in Alto Neuroscience in Q1 2024 and held it in 1 quarter.
Macquarie Group's Alto Neuroscience position peaked at $7 in Q1 2024.
58 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.